425: Waters Reports Strong Q2, Eyes BD SpinCo Merger

Waters Corporation announced strong second-quarter 2025 financial results and provided an update on its proposed business combination with Augusta SpinCo Corporation, a subsidiary of Becton, Dickinson and Company.

Summary

• Q2 2025 Revenue reached $771 million, representing a 9% reported growth and 8% constant currency (CC) growth year-over-year.
• Q2 2025 Non-GAAP Diluted Earnings Per Share (EPS) was $2.95.
• Constant currency instrument growth was +4%, while constant currency recurring revenue growth was +11%.
• Liquid Chromatography (LC) and Mass Spectrometry (MS) products achieved +11% growth in constant currency.
• The Waters Division reported a +10% constant currency revenue growth, while the TA Division saw a -6% constant currency revenue decline.
• Full-year 2025 guidance projects reported revenue growth of +5.0% to +7.0% and non-GAAP EPS of $12.95 to $13.05.
• Q3 2025 guidance anticipates reported revenue growth of +4.5% to +6.5% and non-GAAP EPS of $3.15 to $3.25.
• The proposed business combination with Augusta SpinCo Corporation (SpinCo), a wholly owned subsidiary of Becton, Dickinson and Company (BD), is expected to generate $200 million in cost synergies by Year 3 and $290 million in revenue synergies by Year 5.
• The Microbiology business, part of SpinCo, is identified as a high-quality asset with a $500 million Total Addressable Market (TAM) growing at high single digits, offering significant value creation opportunities.

Sentiment

Score: 8

Explanation: The company reported strong Q2 2025 financial results, exceeding expectations in key areas like revenue and recurring revenue growth. The proposed acquisition of Augusta SpinCo Corporation is presented with compelling cost and revenue synergy targets, indicating a clear strategic path for future value creation and expansion into high-growth diagnostic markets. While transaction risks are acknowledged, the overall tone and detailed plans suggest a positive outlook.

Positives

• Strong Q2 2025 financial performance with 8% constant currency revenue growth and 11% constant currency recurring revenue growth.
• The Waters Division demonstrated robust growth across all geographies, notably Asia (+14% CC) and Europe (+14% CC).
• High single-digit growth in LC & MS instruments (+11% CC) and significant growth in GLP-1 related sales (+70% 1H25 y/y) and PFAS service plan adoption (+55% 1H25 y/y).
• Anticipated transformational value creation from the proposed SpinCo acquisition, with substantial cost ($200M by Year 3) and revenue ($290M by Year 5) synergies.
• The Microbiology business within SpinCo is identified as a high-quality asset with a $500 million TAM growing at high single digits, offering margin uplift and revenue upside.
• Strong commercial execution, innovation launches, and pricing excellence are contributing to overall growth.

Negatives

• The TA Division experienced a -6% constant currency revenue decline in Q2 2025.
• The Academic & Government end market showed a -3% constant currency revenue decline.
• The proposed transaction with SpinCo involves inherent integration risks and potential for unexpected costs.
• Forward-looking statements are subject to various risks and uncertainties, including economic, environmental, regulatory, trade, and political factors.
• BD Biosciences & Dx Solutions standalone growth outlook includes a CY2025E slowdown and headwinds from US Academic & Government and Pharma Drug Discovery, Flow China Export Ban, and BACTEC Supply issues.

Risks

• One or more closing conditions to the proposed transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or otherwise.
• A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions in connection with such approvals.
• The required approval by the stockholders of Waters may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the proposed transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• The occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.
• Evolving legal, regulatory, and tax regimes.
• Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
• Actions by third parties, including government agencies.
• The risk that the anticipated tax treatment of the proposed transaction is not obtained.
• The risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
• Risks related to the disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
• Other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
• The Company is unable to promptly and effectively integrate SpinCo's businesses.
• The credit ratings of the combined company decline following the proposed transaction.

Future Outlook

Waters Corporation projects full-year 2025 reported revenue growth between 5.0% and 7.0% and non-GAAP diluted earnings per share between $12.95 and $13.05. For Q3 2025, reported revenue growth is guided to be between 4.5% and 6.5%, with non-GAAP diluted earnings per share between $3.15 and $3.25. The company anticipates transformational value creation from the proposed business combination with Augusta SpinCo Corporation, expecting significant cost and revenue synergies over the next several years.

Management Comments

• The company is experiencing continued strong momentum.
• Execution, innovation, and growth strategy are delivering results.
• The company is poised for transformational value creation.

Industry Context

The filing highlights growth in specific areas like GLP-1s and PFAS, indicating alignment with current trends in pharmaceutical and environmental analysis. The proposed acquisition of BD's Biosciences & Diagnostic Solutions (SpinCo) suggests a strategic move to expand into broader life sciences and diagnostics markets, leveraging existing expertise in analytical instruments. The focus on microbiology indicates an entry into a stable, high-growth segment within diagnostics.

Comparison to Industry Standards

• Expected cost synergies of $200 million (approximately 5% of the cost base) are presented as a compelling target, noting that EMD Millipore + Sigma Aldrich achieved approximately 8% cost synergies in a comparable transaction.
• The goal to increase SpinCo's service plan adoption from 40-50% to Waters' 2030 target of 55% indicates a strategic effort to align performance with internal benchmarks.
• The microbiology market is described as a '$500M TAM growing HSD,' positioning the acquired business in a favorable market segment.

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction.
• Risk of other litigation, settlements, or investigations that may affect the timing or occurrence of the proposed transaction or result in significant costs.

Stakeholder Impact

• Shareholders: Potential for value creation through synergies and market expansion, but also risks related to transaction completion, integration, and potential stock price volatility.
• Employees: Risks related to retention and hiring key personnel, and potential disruption from the transaction.
• Customers: Potential for enhanced product offerings and service levels post-integration, but also risks of disruption during the transition.
• Suppliers: Potential for changes in relationships due to consolidation or integration.
• Creditors: Risk of credit ratings decline for the combined company following the proposed transaction.

Next Steps

• Filing of a registration statement on Form S-4 by Waters Corporation, including a preliminary and definitive proxy statement/prospectus.
• Filing of a registration statement on Form 10 by SpinCo, serving as an information statement/prospectus in connection with the spin-off from BD.
• Obtaining required regulatory approvals for the proposed transaction.
• Obtaining required approval by Waters stockholders.
• Integration of SpinCo's businesses post-transaction.
• Realization of anticipated cost and revenue synergies over the next 3-5 years.

Key Dates

Recommendation

Waters Corporation delivered robust Q2 2025 results, demonstrating strong operational momentum. The proposed strategic acquisition of Augusta SpinCo from BD is a significant growth catalyst, with management outlining substantial and achievable cost and revenue synergies ($200M and $290M respectively). This move positions Waters for expansion into high-growth diagnostic markets, particularly microbiology, which has a large and growing total addressable market. Despite inherent integration risks common to large transactions, the detailed synergy plans and the company's current performance suggest a compelling long-term value proposition for investors.

Keywords

Waters Corporation, SEC filing, Q2 2025 earnings, financial results, Becton Dickinson, BD, Augusta SpinCo, merger, acquisition, life sciences, analytical instruments, mass spectrometry, chromatography, laboratory solutions, healthcare diagnostics, GLP-1, PFAS, revenue, EPS, synergies